Be on the lookout for a price bounce soon.
The 10-day moving average for RGEN crossed bullishly above the 50-day moving average on July 10, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in of 331 cases, the price rose further within the following month. The odds of a continued upward trend are .
RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for RGEN moved out of overbought territory on July 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 14, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on July 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
RGEN moved below its 50-day moving average on July 14, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for RGEN entered a downward trend on June 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.181) is normal, around the industry mean (24.469). P/E Ratio (247.520) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (16.155) is also within normal values, averaging (42.883).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
a developer of biologic drugs
Industry MedicalSpecialties
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
CTSIX | 39.41 | 0.35 | +0.90% |
Calamos Timpani Small Cap Growth I | |||
FAFGX | 83.13 | 0.34 | +0.41% |
American Funds Growth Fund of Amer 529F2 | |||
OTCRX | 13.89 | N/A | N/A |
Otter Creek Long/Short Opportunity Inv | |||
PMFPX | 23.25 | N/A | N/A |
Principal MidCap S&P 400 Index R5 | |||
JAWWX | 121.99 | N/A | N/A |
Janus Henderson Global Research T |
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
---|---|---|---|---|
RGEN | 100% | +1.40% | ||
DHR - RGEN | 67% Closely correlated | +0.23% | ||
A - RGEN | 66% Closely correlated | +0.43% | ||
BIO - RGEN | 61% Loosely correlated | -0.04% | ||
MTD - RGEN | 61% Loosely correlated | +1.34% | ||
BRKR - RGEN | 60% Loosely correlated | -1.00% | ||
More |